New hope for prostate cancer: immune drug targets recurrence without hormones
NCT ID NCT04019964
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tested the drug nivolumab in 8 men whose prostate cancer returned after initial treatment and who had specific genetic changes (MMR-deficient or CDK12-altered). The goal was to see if nivolumab could lower PSA levels without using hormone therapy. While the approach offers a non-hormonal option, it is not a cure and aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.